34-Year-Old Man Presents With a Soft Tissue Induration in the Right Thigh

Poll

A 34-year-old man presents with a soft tissue induration in the right thigh. A biopsy of the mass is performed. What is your diagnosis?

A 34-year-old man presents with a soft tissue induration in the right thigh.  A biopsy of the mass is performed and is shown below.

What is your diagnosis?

A. Malignant melanoma
B. Peripheral T-cell lymphoma
C. Metastatic carcinoma
D. Rhabdomyosarcoma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Related Content
Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.

TTFields Combo Shows Meaningful Benefits in Pancreatic Adenocarcinoma

Russ Conroy
August 7th 2025
Article
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 7th 2025
Podcast
Symptom specificity is now included in updated guidelines for SCLC relating to LEMS, characterized by proximal muscle weakness and autonomic dysfunction.

NCCN Guidelines Add LEMS Antibody Testing for SCLC

Roman Fabbricatore
August 7th 2025
Article
Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 7th 2025
Podcast
Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

DCISionRT Shows Superiority vs Clinicopathology in Predicting DCIS Risk

Roman Fabbricatore
August 7th 2025
Article
Supporting data for the accelerated approval of dordaviprone come from 5 open-label trials in H3 K27M-mutant diffuse midline glioma.

FDA Grants Accelerated Approval to Dordaviprone in Diffuse Midline Glioma

Russ Conroy
August 7th 2025
Article